230 research outputs found
Cistercian Pavements from Santa Maria de Alcobaça Abbey: first examples of tin-glazed tiles in Portugal
The Mosteiro de Alcobaça (Alcobaça Monastery, founded in 1153) was built
to the image of Clairvaux Abbey, founded by the Cistercian abbot St. Bernard. In many
ways Alcobaça mirrored the original concepts of the Cistercian Order, with an austere
architectural style and shedding signs of richness. The glazed tiles found on the pavement of the deambulatory and some adjacent chapels are some of the first examples of lead-tin glazes in Christian Portugal. For the first time, these tiles were analytically characterized, to determine their chemical composition, production technology and decoration technique. The analytical techniques used were μ-PIXE (particle-induced X-ray emission), SEM-EDS (scanning electron microscopy with energy-dispersive X-ray spectrometry), and μ-Raman spectroscopy
A novel enzymatically-mediated drug delivery carrier for bone tissue engineering applications: combining biodegradable starch-based microparticles and differentiation agents
In many biomedical applications, the performance
of biomaterials depends largely on their degradation
behavior. For instance, in drug delivery applications, the
polymeric carrier should degrade under physiological
conditions slowly releasing the encapsulated drug. The aim
of this work was, therefore, to develop an enzymaticmediated
degradation carrier system for the delivery of
differentiation agents to be used in bone tissue engineering
applications. For that, a polymeric blend of starch with
polycaprolactone (SPCL) was used to produce a microparticle
carrier for the controlled release of dexamethasone
(DEX). In order to investigate the effect of enzymes on the
degradation behavior of the developed system and release
profile of the encapsulated osteogenic agent (DEX), the
microparticles were incubated in phosphate buffer solution
in the presence of a-amylase and/or lipase enzymes (at
physiological concentrations), at 37 C for different periods
of time. The degradation was followed by gravimetric
measurements, scanning electron microscopy (SEM) and
Fourier transformed infrared (FTIR) spectroscopy and the
release of DEX was monitored by high performance liquid
chromatography (HPLC). The developed microparticles
were shown to be susceptible to enzymatic degradation, as observed by an increase in weight loss and porosity with
degradation time when compared with control samples
(incubation in buffer only). For longer degradation times,
the diameter of the microparticles decreased significantly
and a highly porous matrix was obtained. The in vitro
release studies showed a sustained release pattern with
48% of the encapsulated drug being released for a period of
30 days. As the degradation proceeds, it is expected that
the remaining encapsulated drug will be completely
released as a consequence of an increasingly permeable
matrix and faster diffusion of the drug. Cytocompatibility
results indicated the possibility of the developed microparticles
to be used as biomaterial due to their reduced
cytotoxic effects
Framework to Support the Process of Decision-Making on Life-Sustaining Treatments in the ICU: Results of a Delphi Study
Objectives: To develop a consensus framework that can guide the process of decision-making on continuing or limiting life-sustaining treatments in ICU patients, using evidence-based items, supported by caregivers, patients, and surrogate decision makers from multiple countries. Design: A three-round web-based international Delphi consensus study with a priori consensus definition was conducted with experts from 13 countries. Participants reviewed items of the decision-making process on a seven-point Likert scale or with open-ended questions. Questions concerned terminology, content, and timing of decision-making steps. The summarized results (including mean scores) and expert suggestions were presented in the subsequent round for review. Setting: Web-based surveys of international participants representing ICU physicians, nurses, former ICU patients, and surrogate decision makers. Patients: Not applicable. Interventions: Not applicable. Measurements and Main Results: In three rounds, respectively, 28, 28, and 27 (of 33 invited) physicians together with 12, 10, and seven (of 19 invited) nurses participated. Patients and surrogates were involved in round one and 12 of 27 responded. Caregivers were mostly working in university affiliated hospitals in Northern Europe. During the Delphi process, most items were modified in order to reach consensus. Seven items lacked consensus after three rounds. The final consensus framework comprises the content and timing of four elements; three elements focused on caregiver-surrogate communication (admission meeting, follow-up meeting, goals-of-care meeting); and one element (weekly time-out meeting) focused on assessing preferences, prognosis, and proportionality of ICU treatment among professionals. Conclusions: Physicians, nurses, patients, and surrogates generated a consensus-based framework to guide the process of decision-making on continuing or limiting life-sustaining treatments in the ICU. Early, frequent, and scheduled family meetings combined with a repeated multidisciplinary time-out meeting may support decisions in relation to patient preferences, prognosis, and proportionality
Production of vegetable oil blends and structured lipids and their effect on wound healing
Two oil blends (sunflower/canola oils 85/15 (BL1) and canola/linseed oils 70/30 (BL2)), were prepared and enzymatically interesterified to be applied to surgically-induced wounds in rats. Following surgery, the animals were submitted to the Treatment with Physiological Saline (TPS) (control group), Blends (TBL), and Structured Lipids (TSL). The control group (TPS) received physiological saline solution for 15 days. In TBL, BL1 was administered during the inflammation phase (days 0-3) and BL2 in the tissue formation and remodeling phase (days 4-15). In TSL, Structured Lipid 1 (SL1) and Structured Lipid 2 (SL2) were used instead of BL1 and BL2, respectively. The aim of this study was to compare wound closure evolution among rats treated with the blends or structured lipids versus control rats treated with physiological saline. The wound healing process was evaluated by measuring the wound areas along the treatments and the concentrations of cytokines. An increase in the areas of wounds treated with the blends and structured lipids in the inflammatory phase was observed, followed by a steeper closure curve compared to wounds treated with physiological saline. The changes observed during the inflammatory phase suggest a potential therapeutic application in cutaneous wound healing which should be further investigated.</p
ϒ production in p–Pb collisions at √sNN=8.16 TeV
ϒ production in p–Pb interactions is studied at the centre-of-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03 < ycms < 3.53 and −4.46 < ycms < −2.96, down to zero transverse momentum. In this work, results on the ϒ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the ϒ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the ϒ(2S) nuclear modification factor is evaluated, suggesting a suppression similar to that of the ϒ(1S). A first measurement of the ϒ(3S) has also been performed. Finally, results are compared with previous ALICE measurements in p–Pb collisions at √sNN = 5.02 TeV and with theoretical calculations.publishedVersio
- …